Pain and Swelling after Percutaneous Endoscopic Gastrostomy Removal: An Unexpected Evolution

• Main Authors: Patrícia Queirós, Diamantino Sousa, Artur Antunes, Mercedez Sanchez, Ricardo França, José Casquilho, Horácio Guerreiro
• Format: Article
• Language: English
• Published: Karger Publishers 2018-03-01
• Series: GE: Portuguese Journal of Gastroenterology
• Subjects: Percutaneous endoscopic gastrostomy; Metastasis; Head and neck cancer
• Online Access: https://www.karger.com/Article/FullText/487157
• ISSN: 2341-4545; 2387-1954

Gastrostomy site metastization is considered an uncommon complication of percutaneous endoscopic gastrostomy (PEG) placement in patients with head and neck tumours, but it is important to consider this possibility when evaluating gastrostomy-related symptoms. The authors present the case of a 40-year-old male with excessive alcohol consumption and active smoking, diagnosed with a stage IV oropharyngeal squamous cell carcinoma. The patient developed a paraneoplastic demyelinating motor polyneuropathy that, associated with tumour mass effect, caused dysphagia with need for nasogastric tube feeding. Treatment with radiotherapy and then chemoradiotherapy was administered and a PEG was placed with the pull method. Cancer remission and resolution of polyneuropathy was achieved, so PEG was removed. Two weeks later, the patient presented with pain and swelling at the gastrostomy site suggesting a local abscess, with improvement after drainage and antibiotic therapy. After 1 month, there was a tumour mass at the gastrostomy site and an oropharyngeal cancer metastasis was diagnosed. The patient underwent surgical excision of abdominal wall metastasis and abdominal disease was controlled. Nevertheless, there was subsequent oropharyngeal neoplasia recurrence and the patient died 6 months later. This case raises the discussion about gastrostomy placement methods that could avoid gastrostomy site metastization, the possible differential diagnosis, and diagnostic workout. Surgical resection may allow metastatic disease control, but by primary disease evolution greatly affects prognosis.